Final results of the Canadian prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters

Cancer

Volumn 107, Issue 2, 2006, Pages 389-395

  Bruchovsky, Nicholas ^a,f   Klotz, Laurence ^b   Crook, Juanita ^c   Malone, Shawn ^d   Ludgate, Charles ^e   Morris, W James ^e   Gleave, Martin E ^a   Goldenberg, S Larry ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Biochemical recurrence; Intermittent androgen suppression; Prostate cancer; Radiotherapy

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; FOLLOW UP; HORMONE INHIBITION; HUMAN; MALE; MULTICENTER STUDY; ORGAN SIZE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE SIZE;

AGED; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CANADA; CYPROTERONE ACETATE; HUMANS; LEUPROLIDE; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 33745813551     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21989     Document Type: Article

References (38)

1. Lesser B, Bruchovsky N. The effects of 5α-dihydrotestosterone on the kinetics of cell proliferation in rat prostate. Biochem J. 1974;142:483-489.
2. Lesser B, Bruchovsky N. Effect of duration of the period after castration on the response of the rat ventral prostate to androgens. Biochem J. 1974;142:429-431.
3. Lesser B, Bruchovsky N. The effects of testosterone, 5α- dihydrotestosterone and adenosine 3́,5́-monophosphate on cell proliferation and differentiation in rat prostate. Biochim Biophys Acta. 1973;308:426-37.
4. Bruchovsky N, Lesser B, Van Doom E, Craven S. Hormonal effects on cell proliferation in rat prostate. Vitam Horm. 1975;33:61-102.
5. Foulds L. Neoplastic development, vol 1. New York: Academic Press, 1969;73.
6. Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res. 1977;37:82-94.
7. Bruchovsky N, Rennie PS, Van Doom E, Noble RL. Pathological growth of androgen-sensitive tissues resulting from latent actions of steroid hormones. J Toxicol Environ Health. 1978;4:391-408.
8. Bruchovsky N, Goldie JH. Basis for the use of drug and hormone combinations in the treatment of endocrine-related cancer. In: Bruchovsky N, Goldie JH, editors. Drug and hormone resistance in neoplasia, vol II, clinical concepts. Boca Raton: CRC Press, 1983:129-162.
9. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993;71:2782-2790.
10. Minesita T, Yamaguchi K. An androgen-dependent tumor derived from a hormone-independent spontaneous tumor of a female mouse. Steroids. 1964;4:815-829.
11. Bruchovsky N, Sutherland DJA, Meakin JW, Minesita T. Androgen receptors: relationship to growth response and to intracellular androgen transport in nine variant lines of the Shionogi mouse mammary carcinoma. Biochim Biophys Acta. 1975;381:61-71.
12. Bruchovsky N, Rennie PS, Goldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990;50:2275-2282.
13. Akakura K, Bruchovsky N, Rennie PS, et al. Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (Clusterin) gene in the Shionogi carcinoma. J Steroid Biochem Mol Biol. 1996;59:501-511.
14. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986;58:2546-2550.
15. Goldenberg SL, Bruchovsky N, Cleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995;45:839-844.
16. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology. 1996;48:800-804.
17. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol. 1996;30(Suppl 1):22-25.
18. Oliver RTD, Williams G, Paris AMI, Blandy JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology. 1997;49:79-82.
19. Theyer G, Holub S, Durer A, et al. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer. 1997;75:1515-1518.
20. Grossfeld CD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998;51:137-144.
21. Horwich A, Huddart RA, Gadd J, et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol. 1998;81:96-99.
22. Bruchovsky N, Goldenberg L, Cleave M. Intermittent androgen suppression for the treatment of prostate cancer. In: Belldegrun A, Kirby RS, Oliver RTD, editors. New perspectives in prostate cancer. Oxford: Isis Medical Media, 1998:273-282.
23. Crook JM, Szumacher E, Malone S, Huan S, Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology. 1999;53:530-534.
24. Bruchovsky N, Klotz LH, Sadar MD, et al. Intermittent androgen suppression for prostate cancer: Canadian prospective trial and related observations. Mol Urol. 2000;4:191-201.
25. Strum SB, Scholz MC, McDermed JE. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy. Oncologist. 2000;5:45-52.
26. Bouchot O, Lenormand L, Karam G, et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol. 2000;38:543-549.
27. Prapotnich D, Fizazi K, Escudier B. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol. 2003;43:233-239.
28. Albrecht W, Collette L, Fava C, et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol. 2003;44:505-511.
29. De La Taille A, Zerbib M, Conquy S, et al. Intermittent androgen suppression in patients with prostate cancer. BJU Int. 2003;91:18-22.
30. Lane TM, Ansell W, Farrugia D, et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int. 2004;73:117-122.
31. Bruchovsky N, Theyer G. Second international workshop on intermittent androgen ablation therapy, meeting report. Eur Urol Today. 2000;11:4-5.
32. de Levai J, Boca P, Yousef E, et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer. 2002;1:163-171.
33. Calais da Silva F, Bono A, Whelan R et al. Intermittent androgen deprivation for locally advanced prostate cancer. Preliminary experience from an ongoing randomized controlled study of the South European Urooncological Group. Oncology. 2003;65(Suppl 1):24-28.
34. Pether M, Goldenberg SL. Intermittent androgen suppression. BJU Int. 2004;93:258-261.
35. Sato N, Akakura K, Isaka S, et al. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology. 2004;64:341-345.
36. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J Urol. 1991;145:984-987.
37. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocr Relat Cancer. 1999;6:487-502.
38. Sato N, Cleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model. J Steroid Biochem Mol Biol. 1996;58:139-146.